Controversies and Questions in the Surgical Treatment of Melanoma
|
|
- Willis Harrell
- 5 years ago
- Views:
Transcription
1 Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School of Medicine
2 Financial Disclosures Consultant AMGEN, Castle Biosciences No relevant financial disclosures for this presentation
3 Clinical Questions/Controversies Three Clinical questions: 1. Who should get a SLN biopsy with thin ( 1.00 mm) melanoma? Are there low risk groups among patients with intermediate depth melanoma? 2. What are outcomes of patients who have a positive SLN biopsy with thin melanoma? How do they compare to those who develop clinical nodal disease? 3. Should patients with a positive SLN go on to get a completion lymph node dissection?
4 Reasons for SLN biopsy Prognostication/Staging Therapeutic value? Regional control of disease
5 Morbidity of SLN biopsy Lymphedema rates ~5% Infection <5% Hematoma < 5% Seroma 5-10% Parasthesias 5-10% Anaphylaxis from dye injection <<1%
6 Clinical case #1 48 M with a 0.71 mm thick melanoma on the back, Clark level IV, 1 mitoses/mm2 (non-ulcerated, no LVI, no regression)
7 Predictors of SLN positivity in patients with Thin Melanoma Thin (T1) melanomas ( 1.00 mm) account for approximately 60-70% melanomas SLN positivity in this group is < 5% Current NCCN guidelines recommend discussing and considering SLN biopsy in T1a melanomas 0.76 mm and offering SLN biopsy in T1b melanomas 0.76 mm Little consensus as to which factors should drive decision for SLN biopsy in T1 lesions <0.76 mm
8 ASCO/SSO Guidelines for SLN biopsy Wong et al. JCO 2012; 30 (23):
9 NCCN guidelines for SLN biopsy Version Stage IA,B ( 0.75 mm any features*) WE alone Stage IA ( mm) WE, consider SLN Stage IB ( mm)/ II WE; discuss and offer SLN
10 Predictors of SLN positivity in patients with Thin Melanoma Bartlett, Karakousis et al Ann Surg Onc 2014
11 Predictors of SLN positivity in patients with Thin Melanoma Bartlett, Karakousis et al Ann Surg Onc 2014
12 Predictors of SLN positivity in patients with Thin Melanoma NCDB database T1 melanomas 0.5mm who had nodal evaluation 8,772 Thickness, ulceration, mitoses, Clark level, LVI, age ASC abstract submission 2017
13 Predictors of SLN positivity in patients with Thin Melanoma T Stage T1a T1b Age Total patients <0.76mm Positive Nodes, n (%) NCCN Guidelines Total patients 0.76mm Positive Nodes, n (%) NCCN Guidelines <40y (0.9) NR (6.9) Consider 40-65y (2.0) NR (4.2) Consider 65y (2.7) NR (1.1) Consider <40y (5.6) NR (7.1) Offer 40-65y (3.0) NR (6.4) Offer 65y (2.0) NR (3.9) Offer ASC abstract submission 2017
14 Low Risks groups for SLN positivity in Patients with Intermediate Depth Melanoma
15 Predictors of SLN positivity-intermediate Thickness Melanoma Bartlett, Karakousis et al ASO 2015
16 Predictors of SLN positivity: Intermediate-Thickness Melanoma Bartlett, Karakousis et al ASO 2015
17 Outcomes of Patients with Thin Melanoma after SLN biopsy
18 Outcomes of Patients undergoing SLN biopsy Final trial report MSLT-1 Among patients with nodal metastases, those who underwent SLN biopsy with immediate lymphadenectomy demonstrated improved survival in intermediate thickness group but not thick group. Morton et al NEJM 2014
19 Melanoma Databases Outcomes of Thin Melanoma Patients undergoing SLN biopsy Penn-JWCI study N=586 CNR (Clinical Nodal Recurrence) N=466 SLN+ pts N=120 Univariable Analysis Multivariable Analysis* Characteristic HR 95% CI p- value HR 95% CI p-value Sex Female Ref Male 1.06 ( ) Age 50 years Ref > 50 years 1.35 ( ( ) 1.81) Primary Extremity Ref Ref Site Axial 1.40 ( ( ) 1.85) Breslow 0.75 Ref (mm) > ( ) Clark I-III Ref Level IV-V 1.08 ( ) Unknown 0.78 ( ) Ulceration Absent Ref Ref Present 1.79 ( ( ) 3.01) Unknown 1.89 (1.46- < (1.27- < ) ) Nodal SLN Ref Ref Evaluation CNR 3.42 ( ) < ( ) <0.001 Karakousis, Faries et al Ann Surg Onc 2016
20 Outcomes of Thin Melanoma Patients undergoing SLN biopsy SLN + Months Clinical Nodal Recurrence P< Survival Probability SLN + Penn Penn JWCI Clinical Nodal Recurrence JWCI }SLN + }CNR P< Months
21 SLN biopsy in Patients with Thin Melanoma NCDB database T1 melanomas 0.76 mm 20,293 patients 13,944 underwent nodal evaluation (NE) Nodal positivity rate 3.9% NE evaluated NE not evaluated 89.7% ( )* 84.8% ( )* *5y OS (p<0.001) SSO abstract submission 2017
22 Regional Control with Lower Morbidity MSLT-1 If there is not a therapeutic role to SLN biopsy, is there a benefit with respect to earlier regional control of disease? Faries et al. Ann Surg Onc 2010; 17:
23 Regional Control with Less Morbidity No significant difference in acute morbidity between immediate and delayed lymphadenectomy group Mean Hospital stay longer in the delayed lymphadenectomy group (9.9 days) versus immediate group (8.3 days), although this could probably largely be accounted for by increased number of deep groin dissections Lymphedema rates higher in delayed versus early lymphadenectomy group Faries et al. Ann Surg Onc 2010; 17:
24 Clinical case #2 42 F with 2.3 mm thick non-ulcerated left leg melanoma with 1/2 + SLNs (0.4 mm micrometastasis intraparenchymal) Should patients with a positive SLN go on to get a completion lymph node dissection?
25 Completion lymphadenectomy or not for +SLN Incidence of finding additional non-sentinel nodes on completion lymphadenectomy for a + SLN is approximately 15-20% Various factors may help to predict which patients are at risk for harboring additional metastatic disease in the non-sentinel nodes Disease in the non-sentinel nodes may portend a worse prognosis Completion lymphadenectomy has been the standard approach for patients with + SLN, but randomized trial is currently underway to address the impact of this approach on melanoma-specific survival
26 Predictors of non-sentinel LN positivity Van der Ploeg et al. JCO 2011; 29 (16):
27 Predictors of non-sentinel LN positivity 2 nodes mo P< mo p= mo 34 mo Ariyan et al. Ann Surg Onc 2009; 16:
28 DECOG study Leiter et al. Lancet Oncology 2016; 17 (6):
29 DECOG study Distant metastasis free survival Overall survival Leiter et al. Lancet Oncology 2016; 17 (6):
30 MSLT2 Study MSLT2 (N=1,939 proposed randomized pts with +SLN) Completion lymphadenectomy Observation with serial U/S Currently, completed accrual
31 Conclusions SLN biopsy is routinely offered to patients with T2 or greater melanomas ( 1 mm) and in patients with T1b lesions 0.76 mm SLN biopsy scan be selectively considered in other T1 lesions (+ deep margin, LVI, Clark level IV/V, high mitotic count) Primary value of SLN biopsy is prognostic/staging and therefore risks of procedure must be weighed against potential benefits. There may be therapeutic value, and increasingly so as newer adjuvant regimens are developed that can be used earlier in stage III disease. Completion lymphadenectomy remains the standard approach for patients with + SLN pending the results of the MSLT2 trial.
32 Thank you
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationNo Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma
No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma Michael Lowe, MD Assistant Professor of Surgery Winship Cancer Institute Emory University School of Medicine July
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationThin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis
Ann Surg Oncol DOI 10.1245/s10434-016-5646-9 ORIGINAL ARTICLE MELANOMAS Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis Giorgos
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationUpdate on Lymph Node Management in Melanoma
Update on Lymph Node Management in Melanoma John T. Vetto MD, FACS Professor of Surgery Division of Surgical Oncology Oregon Health & Science University Portland, Oregon Lymph Nodes in Melanoma Outline
More informationSurgery for Melanoma and What s on the Horizon
and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationPrecision Surgery for Melanoma
Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationWhat are the new AJCC Staging System changes, and how will they affect my patients?
What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationSurgical Oncology Perspective of Melanoma
Surgical Oncology Perspective of Melanoma Hans F. Schoellhammer, MD, FACS Assistant Clinical Professor Division of Surgical Oncology September 20, 2018 Nothing to disclose DISCLOSURE Discussion Objectives
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationClinical utilities and biological characteristics of melanoma sentinel lymph nodes
W J C O World Journal of Clinical Oncology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5306/wjco.v7.i2.174 World J Clin Oncol 2016 April
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationSLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA
Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationSurgical Treatment of Melanoma Across the Disease Spectrum:
AOCD Annual Fall Meeting October 28 th, 2017 New Orleans, Louisiana Surgical Treatment of Melanoma Across the Disease Spectrum: Standards of Care and Evolving Paradigms Merrick Ross, M.D. Professor of
More informationWhen Do I Consider Myself Cured?
The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationTumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?
Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationPrinted by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
Table of Contents NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationAn estimated 76,690 patients will be diagnosed with invasive
SONDAK ET AL Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma Vernon K. Sondak, MD, Sandra L. Wong, MD, Jeffrey E. Gershenwald, MD, and John F. Thompson,
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationIncreasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
More informationTherapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
Ann Surg Oncol () : DOI.45/s44--74- ORIGINAL ARTICLE MELANOMAS Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
More informationSentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma
Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma John A Zitelli MD Adjunct Clinical Associate Professor Dermatology, Otolaryngology, Plastic Surgery University of Pittsburgh
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationSeventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Melanoma Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationClinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationEVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY
EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY AXILLARY LYMPH NODE METASTASIS Axillary lymph node metastasis is one of the most
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationResearch Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre
Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationSession Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic
Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications Andres A. Roma, MD Cleveland Clinic No Disclosures In the past 12 months, I have not had
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationResults, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de
University of Groningen Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de IMPORTANT NOTE: You are advised to consult the publisher's
More informationMELANOMA: HANDS-ON OR HANDS-OFF?
MELANOMA: HANDS-ON OR HANDS-OFF? M SCHAMM MBChB (Pret), FCS (SA) Endocrine and Transplant Surgeon, Department of Surgery, University of the Witwatersrand; and Clinical Head Transplant Surgery, Charlotte
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More informationManagement of the patient with Lymph Node Involvement. Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne
Management of the patient with Lymph Node Involvement Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne Lymph Node Field Recurrence Most important prognostic factor for early stage melanoma
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationSentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma
Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma S. Ross Patton, MD - PGY III Faculty Mentor: Susan McCammon, MD The University of Texas Medical Branch (UTMB Health) Department of Otolaryngology
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationDENOMINATOR: All melanoma pathology reports for primary malignant cutaneous melanoma
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:
More informationManagement of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial
DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.
More information